SOUTH ORANGE, N.J., November 6, 2025 — Nephros, Inc. (Nasdaq: NEPH), a leader in water filtration solutions for the medical and commercial sectors, announced record-breaking third-quarter results, marking its fourth consecutive quarter of profitability. The company reported net revenue of $4.8 million, a 35% increase year-over-year, underscoring the growing demand for advanced water safety and filtration technologies across infection control, dialysis, and commercial markets.
Science Significance
Nephros’ scientific innovation continues to center around water purity and pathogen control, vital for healthcare environments where infection prevention is critical. The company’s launch of its PFAS filtration solution in early October represents a significant technological advancement targeting per- and polyfluoroalkyl substances, harmful contaminants increasingly found in public water systems. These filtration solutions leverage membrane-based scientific engineering, enhancing microbial safety and supporting compliance with clinical-grade water standards essential to dialysis and hospital sterilization systems.
Regulatory Significance
The company’s consistent focus on FDA-compliant filtration systems and regulatory-grade water quality assurance positions Nephros strongly within the MedTech regulatory landscape. The introduction of PFAS-targeting filters aligns with tightening EPA and FDA guidelines on emerging contaminants, reinforcing the company’s commitment to meeting evolving compliance benchmarks. Its regulatory adherence supports hospital accreditation standards and environmental health safety requirements, critical for maintaining patient safety and operational integrity across healthcare facilities.
Business Significance
Advertisement
Nephros achieved its highest level of programmatic sales in company history, fueled by customer engagement initiatives like on-site training, webinars, and service expansions. The company’s net income surged 84% to $337,000, with Adjusted EBITDA up 42%, showcasing robust profitability and operational efficiency. CEO Robert Banks emphasized that these achievements reflect “a disciplined focus on customer-centered initiatives” and innovation. With $5.2 million in cash reserves, no debt, and a strong innovation pipeline, Nephros is strategically positioned for sustained growth and market expansion across both healthcare and industrial sectors.
Patients’ Significance
For patients in dialysis centers, hospitals, and long-term care facilities, Nephros’ filtration technology plays a direct role in protecting health outcomes by ensuring pathogen-free water. The company’s innovations help reduce nosocomial infection risks, contributing to higher patient safety standards and better clinical outcomes. By addressing contaminants like PFAS, Nephros also helps safeguard the broader public from chronic exposure, aligning with preventive healthcare goals and the global sustainability agenda.
Policy Significance
Nephros’ initiatives align with public health policies emphasizing environmental protection and clinical safety. The company’s new PFAS filtration product supports government efforts under the Safe Drinking Water Act (SDWA) and EPA’s PFAS Roadmap, while its medical filtration systems reinforce CDC infection control frameworks. By bridging public health policy and industrial technology, Nephros contributes to the broader national and global push for clean water accessibility and health system resilience.
With its unbroken streak of profitability, expanded product portfolio, and commitment to scientific and regulatory excellence, Nephros continues to define the future of water safety and healthcare filtration technology. As the company accelerates into 2026, its innovation-driven strategy promises to deliver sustainable impact, public health value, and business resilience in an increasingly compliance-focused global market.
Source: Nephros, Inc. press release
